医学
替代医学
临床试验
安慰剂
传统医学
报告审判综合标准
随机对照试验
中医药
梅德林
研究设计
家庭医学
质量(理念)
科学网
数据提取
描述性统计
荟萃分析
物理疗法
透明度(行为)
系统回顾
重症监护医学
第N部分,共1次审判
临床研究设计
相对风险
作者
Jingyi Yu,Sai Jiang,Yuxing Wang,Hejing Pan,Hui Liu,Xuanlin Li,Yuehua Chen,Chengping Wen
标识
DOI:10.1016/j.phrs.2026.108244
摘要
This cross-sectional study aimed to characterize the design, application, and reporting standards of Chinese herbal medicine placebos (CHM-placebos) in randomized controlled trials (RCTs) published between 2018 and 2025. We searched the Web of Science database for RCTs involving Chinese herbal medicine (CHM) and matching placebos published from January 2018 to September 2025. Methodological quality was assessed using Risk of Bias Instrument for Use in Systematic reviews for Randomized Controlled trials (ROBUST-RCT). Reporting compliance was evaluated according to the Consolidated Standards of Reporting Trials (CONSORT) Extension for Chinese Herbal Medicine Formulas (CONSORT-CHM). Descriptive statistics summarized features of CHM-placebos’ design. A total of 136 trials were included. Methodological assessment revealed that “Allocation concealment” had the highest risk (definitely high risk: 4%, probably high risk: 19%). Reporting compliance with CONSORT-CHM placebo-specific items was low, only 16 trials (11.76%) fully reported the name and amount of each ingredient, 6 trials (4.41%) trials reported quality control and safety assessments, and 9 trials (6.62%) provided complete production information. Manufacturers’ information was reported in 90 trials (66.18%). 33 trials (24.26%) reported that their CHM-placebos contained traditional Chinese medicine ingredients, with two trials using placebos composed entirely of TCM. Deficiencies persist in the CHM-placebos’ design and reporting, especially regarding compositional transparency and quality verification. The use of CHM-placebos containing TCM ingredients challenges the fundamental principle of pharmacological inertness. • A great amount of CHM-placebos contain TCM ingredient, even up to 100%. • Randomized placebo-controlled trials of CHM have low compliance to the CONSORT-CHM. • The information of CHM-placebos are reported seriously incompletely, especially for quality control, safety assessment and production information. • The information of CHM-placebos in trials with cooperation between nations, multi-center design and high impact factors have more sufficient report.
科研通智能强力驱动
Strongly Powered by AbleSci AI